Xu, W., Weng, J., Zhao, Y., Xie, P., Xu, M., Liu, S., Yu, Q., Yu, M., Liang, B., Chen, J., Sun, H.-C., Li, H., Ye, Q., Shen, Y.

FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma

2 de May de 2025 by Xu, W., Weng, J., Zhao, Y., Xie, P., Xu, M., Liu, S., Yu, Q., Yu, M., Liang, B., Chen, J., Sun, H.-C., Li, H., Ye, Q., Shen, Y.

Background
The efficacy of immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) is limited by heterogeneity in individual responses to therapy. The heterogeneous phenotypes and crucial roles of cancer-associated fibroblasts (CAFs) in…